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Abstract
Reports that two young children developed leukemia after being treated for immunodeficiency
with their own retrovirally modified bone-marrow cells delivered a severe blow to confidence in
gene therapy as a treatment. Two reports, published since the trial was initiated, now take away
some of the mystery as to why these events happened and allay fears for the safety of gene
therapy across all therapeutic applications. 
Published: 29 July 2004
Genome Biology 2004, 5:237
The electronic version of this article is the complete one and can be
found online at http://genomebiology.com/2004/5/8/237
© 2004 BioMed Central Ltd 
“Friends, Romans, countrymen, lend me your ears;
I come to bury Caesar, not to praise him.
The evil that men do lives after them;
The good is oft interred with their bones;
So let it be with Caesar. The noble Brutus
Hath told you Caesar was ambitious;
If it were so, it was a grievous fault,
And grievously hath Caesar answer’d it.” 
Mark Antony, in Julius Caesar by William Shakespeare.
Recent findings have shown that that two young children
treated by gene therapy to reverse their profound immune
deficiency developed leukemia as a direct result of the
experimental protocol [1,2]. These reports follow the tragic
death of a young man after treatment with an adenoviral vector
[3] and a more generalized sense of disappointment that the
seemingly over-ambitious aspirations of gene therapists have
not lived up to expectations. Against this backdrop, it is easy to
feel a certain comradeship with Mark Antony, as he prepared
to deliver his oration for the assassinated Emperor Julius
Caesar in Rome. Brutus had just finished justifying to the
assembled masses the apparently compelling reasons for the
recent assassination based upon fears that Caesar’s ambition
had turned from nobility into dangerous liability. So it is now
with gene therapy, where whispering voices suggest that the
ambitions of this field have outstretched its capabilities.
Even the likes of Mark Antony might struggle to marry
compassionate appreciation of previous problems, which
will no doubt recur, with the eloquence to convince an
audience that this remains a discipline where remarkable
advances have been achieved. 
The leukemias induced in two of ten children treated with
gene therapy for an immuno-deficiency syndrome came as a
double dagger blow to the heart of the gene-therapy field.
These children were born with X-linked severe combined
immunodeficiency (SCID-X1), which is caused by the genetic
loss of the gene encoding common  chain of the interleukin-2
receptor (IL-2Rc) in mature T cells. Bone-marrow stem
cells from the ten children were removed and infected with a
retroviral vector encoding IL-2Rc [4]; the treated stem cells
were then re-infused into the children with the hope that the
stably expressed, and integrated, IL-2Rc gene would
restore immune function to T cells as they re-populated the
patients, thereby conferring systemic immune competency.
This would permit the children, if all went well, to lead a life
free of intensive quarantine [4]. But three years after the
therapy was administered two of the children developed
T-cell leukemia [1,2]. Not only did the leukemias originate
from the re-infused T cells, but it has become clear that the
integration of the retroviral vector was itself a major driverin the evolution of the leukemic phenotype [2]. In particular,
the leukemic cells from both patients had integrations of
the vector very close to a cellular gene called LMO2  [2],
deregulation of which has been observed in human T-cell
leukemias [5]. 
As distressing as these reports have been, there is a second
reason for profound disappointment at the outcome of the
SCID-X1 trials. The findings of treatment-induced disease
have inevitably deflected what was beginning to build into
huge elation at the fact that, in 9 out of 10 of the treated chil-
dren, the therapy had really worked [6]. This trial did, and
still does, represent a truly remarkable triumph as the first
unequivocal success for gene therapy. Many of the treated
children have been able to resume normal lives outside of
isolation and their prospects continue to be good. The
finding that gene therapy had converted a severe immune-
deficiency syndrome into a leukemia is therefore a particularly
unwelcome diversion from what would otherwise be banner
headlines stating that gene therapy is finally delivering on its
medical promise. 
Is it yet possible to change the perception that success can only
go hand in hand with harm, as in the SCID trial, for any gene-
therapy endeavor in the future? What would it take to reverse
the tide of opinion mounting against the over-reaching ambi-
tion of gene therapy? One way to change opinions would be
to obtain evidence for a uniqueness and specificity associated
with these adverse clinical events, so as to suggest that they
do not represent the inevitable face of things to come for any
protocol involving gene transfer. Such evidence (to sway
lingering Brutus-like assassins) has now come in the form of
molecular characterization of the etiology of the leukemias in
the two affected children [5,7] and an insightful study
showing why they were not predicted earlier [8]. 
One of the big mysteries has been why the adverse events had
not been predicted by the numerous pre-clinical studies for
the relevant gene therapy trial. A large part of the answer
came in a study reported in 2002 [8], which was, unfortu-
nately, well after initiation of the trial [4]. The 2002 short
report from Li et al. [8] described the development of a
similar leukemia in mice following gene transfer of a retroviral
vector into bone-marrow-derived stem cells (Figure 1). There
were two key aspects of novelty in this report, which explain
why the phenomenon had not been seen before in the pre-
clinical studies supporting the safety of the strategy used in
the children with SCID. The authors used a retroviral vector
to infect bone-marrow cells and re-infused them back into
immunodeficient mice - with obvious parallels to the human
clinical trials that had started a year or so earlier. In these re-
infused mice, no leukemia was observed (Figure 1a). But
because the lifetime of a single mouse may not be long
enough to observe the evolution of fully transforming events -
which are known to require co-operation between changes in
multiple genes - the authors also serially transplanted the
adoptively transferred bone marrow into a further irradiated
(immune-deficient) recipient. Within 22 weeks of the passage
from mouse to mouse, all the animals that received the sec-
ondary transplant developed hematopoietic disorders, and
60% developed an acute myeloid leukemia (Figure 1b). 
These experiments included two critical factors that had not
been tested together prior to initiation of the clinical trials.
The first was that the life time of the transduced, reconsti-
tuted cells was extended beyond a single mouse’s lifetime,
allowing observation of slow-developing, accumulating and
co-operating mutations; and the second factor was that the
modified marrow cells were re-infused into an immunologi-
cally depleted cell compartment. Homeostatic expansion of
the cells was, therefore, both possible and inevitable [9],
allowing for greater proliferation of the transduced cell popu-
lation and the subsequent accumulation of additional genetic
‘hits’ leading to transformation (Figure 1c). The authors
showed that the transgene that had been present in the retro-
viral vector - the dLNGFR gene - was critical to the develop-
ment of disease. The dLNGFR gene is commonly used as a
marker gene for such studies but - and with significant simi-
larities to the IL-2Rc gene used in the human SCID trials - it
is also a growth-factor receptor that could signal potentially
transforming growth signals to transduced cells. Other
marker genes used in the same protocol did not induce
leukemic expansion of infused cells. Also, in a parallel to the
findings from the SCID trial that were soon to emerge [2], all
of the mouse leukemias contained a vector integrated into a
single genetic locus: the murine Evi1 gene (Figure 1c) [8].
Thus, Li et al. [8] report a retroviral vector-induced leukemia
that is dependent upon first, the transgene carried by the
vector; second, the site of integration into the genome of
transduced marrow progenitor cells; and third, a state of
immune deficiency in the recipient hosts resulting in forced
expansion of the transduced T-cell population (Figure 1). 
Insertional mutagenesis, in which a promoter or enhancer in
the vector transactivates the expression of an adjoining
proto-oncogene, or in which the vector itself inactivates a
tumor-suppressor gene, has long been viewed suspiciously as
an unwelcome result of the use of any integrating vector [10].
The frequency of insertional mutagenesis is, however, pre-
dicted to be very low and so it has not been seen as a barrier to
the use of such replication-defective vectors in clinical trials
[10-12]. Nonetheless, even the most committed retrovirologist
cannot fail to be concerned at a frequency of two insertional
mutagenesis-induced leukemias in a group of ten subjects [1].
Therefore, while in no way belittling the significance of a
second patient developing a leukemia, the finding that the eti-
ology of the disease in the second patient was also associated
with the same LMO2 gene paradoxically gave some reassur-
ance [2]. Given the large range of known T-cell proto-onco-
genes, the fact that both cases turned out to have integration
sites around the same cellular gene argues strongly that the
events were disease-, protocol-, and probably cell-type-specific,
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Genome Biology 2004, 5:237as theoretically and mechanistically argued by McCormack
and Rabbitts [5]. This suggestion implies that such adverse
events are not necessarily to be expected following the use of
retroviral vectors in all contexts, an important get-out clause
for the survival of retroviruses as viable vectors. 
The strength of this argument was confirmed recently by a
study driven by the gift of hindsight, in which a search of a
mouse retrovirus-tagged genomic database, containing
insertion-site data from in excess of 3,000 retroviral-
induced hematopoietic tumors, revealed records of two
leukemias associated with insertion at the Lmo2 gene [7].
One leukemia had a retroviral insertion both in the Lmo2
gene and in the IL-2Rc gene - precisely the gene combination
involved in the SCID trial leukemia cases (Figure 2a). The
chances that the leukemic murine cells would have retroviral
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Figure 1 
Unmasking retroviral vector-mediated leukemogenesis following bone-marrow transplantation in the mouse. (a) Li et al. [8] used a replication-defective
retroviral vector, similar to that used in the patient trials [4], but this time encoding a commonly used marker gene dLNGFR. Because the bone-marrow cells
were infected ex vivo, the re-infused population almost certainly contained a clone in which the dLNGFR retroviral vector had established a pre-transforming
environment (thus providing transformation signals 1 and 2 by mechanisms described below). Transplanting this clone into an irradiated mouse meant that the
pre-malignant clone had plenty of immunological space to differentiate into a T cell and then to undergo multiple cell divisions in order to re-populate the
depleted T-cell compartment. In some progeny cells further genetic mutations would occur to mature the transforming process (signals 3 and 4). But within
the life time of the recipient mouse, there was still insufficient expansion of the pre-malignant clone to produce a daughter cell with all of the required signals
for full leukemic transformation. That mouse was therefore phenotypically normal with no apparent disease. This is where many of the pre-clinical studies on
bone-marrow cell transplantation with vector-modified cells were terminated with an apparently safe outcome. (b) Li et al. [8] took the experiment one
critical step further. Transplanting the bone marrow of the first mouse into a second irradiated recipient allowed for further homeostatic expansion of the
pre-malignant cells, which was sufficient for the final necessary transforming mutations (signal 5, or more) to accumulate in the genome and to produce
complete transformation of a single cell. Uncontrolled proliferation of this cell leads to leukemia. (c) Molecular analysis of the leukemias that developed in six
of ten mice in the study by Li et al. [8] revealed the molecular pathways by which the dLNGFR gene could contribute to at least the early, pre-leukemic
mutations. In these gene-replacement trials, the dLNGFR gene was meant to encode an inert molecule to tag infected cells. But it in fact encodes a receptor for
a growth factor (a neurotrophin) and in the construct used by Li et al. [8] it was modified to remove its cytoplasmic domain. This deleted domain is usually
pro-apoptotic. In hematopoietic cells, the deleted version of the receptor can contribute to signaling of growth signals (signal 1) but now presumably without
the pro-apoptotic domain to keep its signaling activities in check. These growth signals alone are insufficient to transform T cells, but in the presence of
additional growth-deregulating mutations within a cell the accumulated signals (1-5, for the sake of example here) can lead to complete malignant
transformation of a T cell. The authors also demonstrated that, in all cases, the vector had integrated into the same cellular locus, the Evi1 gene. Evi1 is a
transcription factor whose deregulation by the viral sequences in a precursor T cell probably provides a second predisposing transforming signal (signal 2 in this
case). Co-operation between the dLNGFR and Evi1 signals would then set the stage for the evolution of further transforming signals (3, 4, 5, and so on) in the
progeny cells as they undergo the enforced homeostatic proliferation described in (b) and (c). 
Bone-marrow 
cell with viral 
integrant
Transplanted into 
an X-irradiated 
mouse
Phenotypically
normal mouse
28 weeks
Homeostatic cell expansion
Acquisition of signals 3 and 4
Bone-marrow
cells with 
integrated 
virus
Signals 1 and 2
dLNGFR dLNGFR Evi1
Pre-malignant population 
transplanted into a second
X-irradiated mouse 
(signals 1 and 2)
Acute myeloid
leukemia 
22 weeks
Further cell expansion
Acquisition of signals 5 and ?
Bone-marrow cell 
with viral integrant 
(signals 1 and 2)
Evi1
Signal 2
dLNGFR
Signal 1
Complete T-cell transformation: leukemia
Cell divisions
+
Mutations ?
+
Time
+
Immunological 
space
Signal 3
Signal 4
Signal 5
(a) (b) (c)insertions at both genes without them being involved in the
leukemogenesis are minimal. The authors therefore suggest
that these data show highly persuasive evidence that the
IL-2Rc and Lmo2 genes can co-operate in the formation of
leukemias (Figure 2a) [7], a proposal that now has consider-
able mechanistic support [5]. It is only a very short step to
connect the introduction of the IL-2Rc gene within a retro-
viral vector that also happens to integrate close to the Lmo2
gene in the patient’s cells with the initiation of cooperative
transformation of the progeny cells of the treated children.
Add to this that the children were themselves immune-
depleted, and therefore would allow enforced expansion of
the transduced marrow cells, and the similarities between
what was observed in the mouse [7,8] and human [2] studies
becomes clear (Figure 2b). 
So why are these combined results of such encouragement
despite being against the backdrop of some potentially
tragic findings? First, they give us confidence that the use of
retroviral, or integrating, vectors for transduction of most
cell types is unlikely to cause cancer at a rate anywhere near
the 20% (or, it is still possible, higher) seen in the SCID trial.
Only under specific circumstances of co-operation between
the vector-encoded gene, the insertion site and the ability of
the transduced cells to expand in the patient, is there likely
to be a significant risk of oncogenesis. Second, the findings
indicate helpful ways in which vectors can be improved for
future clinical development: the inclusion of suicide genes
into the vectors would help in deleting any leukemic cells
that might develop; the exposure of fewer stem cells to the
vector, or inserting fewer copies per cell, will reduce the
chances of leukemogenic clones developing; and other
changes in vector design could be made to reduce the effects
of transactivation of cellular proto-oncogenes. Third, they
demonstrate that animal models can be developed that
would more accurately predict the risks associated with
protocols involving gene transfer into stem cells. Fourth,
and perhaps most importantly, the data demonstrate that
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Figure 2
The retrospective study by Davé et al. [7] sheds light on the molecular mechanisms behind the formation of leukemias in children in the SCID-X1 trial [1,2].
(a) The precedent for T-cell transformation by co-operation between the Lmo2 and IL-2Rc proto-oncogenes. The retrospective database search by Davé et
al. [7] revealed that a murine leukemia, 98-031, had been previously reported in which two separate retroviral insertions had occurred close to the Lmo2 and
IL-2Rc genes. Insertional mutagenesis effects (gray arrows) from the transcriptional elements of these proviruses probably led to the deregulation of
expression of both cellular genes, providing growth-deregulating signals (signals 1 and 2) within the cell. These signals alone were probably insufficient for
leukemogenesis, but they may have set up a transforming loop that allowed the infected cell to proliferate more freely than normal [5]. This in turn allowed the
accumulation of an unknown number of further genetic mutations that, additively, would provide sufficient additional growth-promoting signals to the infected
cell to lead to its complete malignant transformation (signals 3-5, for example). (b) An exactly analogous molecular co-operation is likely to have been
responsible for the evolution of the leukemias in the two children in the SCID trial. In this case, the intentional introduction of a retroviral vector encoding the
IL-2Rc gene into the bone-marrow cells of each patient led to integration into (in one patient, shown here), or close to (in a second patient, not shown), the
LMO2 locus. As in the precursors to the murine leukemic cells, additional mutations were presumably required in order to accumulate sufficient signals for
complete leukemogenesis. For these mutations to occur, the precursor pre-malignant cells would have to undergo multiple cell divisions. The fact that the
patients were immune-deficient provided a fertile environment for homeostatic expansion of these cells, allowing them the time and immunological space
required to acquire the extra mutations to allow emergence of a leukemic clone, just as demonstrated in the study by Li et al. [8]. Importantly, it was only the
findings depicted in (b) that allowed the retrospective analysis shown in (a) to take place. At the time of initiation of the SCID trial, there was no way to predict
that the use of the IL-2Rc therapeutic transgene would lead to the predisposing oncogenic cooperation with the LMO2 gene [5].
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(a) (b)the adverse clinical events seen in the two patients with
SCID are fully understandable in terms of the specific protocol
used. This makes the events no more sinister to the eventual
successful development of gene transfer as a therapeutic
modality than the many thousands of adverse events, including
fatalities, that have characterized the development of other
successful drugs. 
Could the leukemias that developed in the children in the
SCID trial have been predicted in the light of this knowl-
edge? Possibly, but only if the clinical trials had been delayed
until the implications of the model reported by Li et al. [8]
were available, and if the database search performed by the
Copeland group [7] had been carried out prospectively
instead of retrospectively. But Rome was not built in a day. It
would be ludicrous to suggest that the clinical trial should
have been delayed in the hope that (unknown) critical pieces
of data would emerge at a later date: to do so would mean
that no new therapy would ever go into patient trials. And,
over and above all other arguments, there is one that some-
times seems to be missed. If the clinical trials of the SCID
infants had been delayed, what would have become of those
children - including the two who developed leukemias that
have been well controlled (at least so far) - who currently live
a quality of life way beyond that which they would have been
granted in the absence of the gene transfer therapy?
“I speak not to disprove what has happened,
But here I am to speak what I do know.
You all did love Caesar once, not without cause:
What cause withholds you then, to support him now?
O judgment! thou art fled to brutish beasts,
And men have lost their reason. Bear with me”
Mark Antony, in Julius Caesar by William Shakespeare.
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